

VEGA DAILY

Unlock Your Best Quote
Ask VEGA Now!

May 7, 2025

VITAMIN

01

Tianxin Pharmaceutical has recently announced a delay in its "Annual Production of 350 Tons of Cholesterol and 6 Tons of 25-Hydroxy Vitamin D3" project. Originally scheduled to begin operations in July 2025, the launch has now been postponed to July 2026. As of the end of March 2025, a total of 90.41 million RMB (approximately USD12.55 million) had been invested in the project, with 82.71% of the planned fundraising completed. The delay is attributed to fluctuations in market prices. Based on internal assessments and market conditions, the company has reevaluated its process route and equipment plans, aiming to optimize both hardware and software configurations to ensure cost competitiveness and product quality—thus slowing the pace of investment.

AMINO ACID

02

According to market sources, starting May 6, AHB has set the following feed-grade amino acid prices:

Valine:USD1660/MT

Arginine: USD3196/MT

API

03

Hybio Pharmaceutical Co., Ltd., headquartered in Wuhan, has recently received approval from the Korean Ministry of Food and Drug Safety for its liraglutide API. Liraglutide is an analog of human glucagon-like peptide-1 (GLP-1). As a GLP-1 receptor agonist, it performs multiple physiological functions, including glucose-dependent insulin secretion, pancreatic β -cell protection, and delayed gastric emptying to help reduce appetite.

The amoxicillin market has remained relatively stable, with steady supply and demand. Transactions are mostly conducted through negotiation, and the current market price stands at USD27.50/KG. Prices are expected to remain stable in the near term, with future focus on factory production volumes and shifts in demand.

FOOD ADDITIVE

04

Shandong Yuwei Biotechnology Co., Ltd. has recently completed the public announcement phase for its erythritol production line green upgrade and technical transformation project for 20,000 tons/year of dextrin. The total investment amounts to 99.834 million RMB (approximately USD13.86 million), accounting for 1.8% of the company's total investment portfolio.

The project includes process optimizations and technology upgrades for the existing erythritol production line, along with the construction of an auxiliary workshop. Upon completion, the facility is expected to achieve an annual output of 20,000 tons of dextrin.

Founded in May 2022, Shandong Yuwei Biotechnology Co., Ltd. is engaged in a variety of businesses including food production and sales, grain processing, food additive manufacturing, alcoholic beverage production and sales, as well as hazardous chemical operations and production.

Reported by Candice, Shea and Sharon

ONE STOP SOLUTION SUPPLIER

VEGA

www.vegapharma.com


vegamax

www.vegafeed.com

 **Prumix**
Ideas for better health

www.prumix.com

